Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Serplulimab - Shanghai Henlius Biotech

Next Previous
Drug Profile

Serplulimab - Shanghai Henlius Biotech

Alternative Names: Anti-PD-1 monoclonal antibody - Shanghai Henlius Biotech; Anti-PD-I mAb - Shanghai Henlius Biotech; Han Si Zhuang; HANSIZHUANG; Hetronifly; HLX-10; Olizu; Recombinant humanized anti-PD-1 monoclonal antibody - Shanghai Henlius Biotech; Zerpidio

Latest Information Update: 19 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henlix Biotech
  • Developer Henlix Biotech; Intas Pharmaceuticals; PT Kalbe Genexine Biologics; Shanghai Henlius Biotech
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours
  • Preregistration Gastric cancer; Squamous cell cancer
  • Phase III Colorectal cancer
  • Phase II/III Adenocarcinoma
  • Phase II Cervical cancer; Hepatitis B; Liver cancer; Nasopharyngeal cancer
  • Clinical Phase Unknown Rectal cancer
  • Preclinical Lymphoma

Most Recent Events

  • 24 Feb 2026 Shanghai Henlius Biotech entered into an exclusive licensing agreement with Abbott Laboratories for the commercialization of Serplulimab across multiple oncology indications, including Extensive-stage small cell lung cancer (ES-SCLC), in Asia-Pacific, Africa, Central Asia, Eastern Europe, and other emerging markets
  • 15 Feb 2026 Preregistration for Gastric cancer (Adjuvant therapy, Neoadjuvant therapy, Combination therapy) in European Union (Parenteral) prior to February 2026 (Shanghai Henlius Biotech pipeline, February 2026)
  • 15 Feb 2026 Preregistration for Squamous cell cancer (Metastatic disease, Combination therapy) in European Union (Parenteral) prior to February 2026 (Shanghai Henlius Biotech pipeline, February 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top